Cantitate/Preț
Produs

Glioblastoma, Part II: Molecular Targets and Clinical Trials, An Issue of Neurosurgery Clinics of North America: The Clinics: Surgery, cartea 32-2

Editat de Linda M. Liau
en Limba Engleză Hardback – 18 apr 2021
This issue of Neurosurgery Clinics, guest edited by Dr. Linda M. Liau, is dedicated to Glioblastoma: Molecular and Clinical Trials. This issue is one of four selected each year by the series consulting editors, Drs. Russell R. Lonser and Daniel K. Resnick. Topics will include-but are not limited to-Pathology & Molecular Markers, Cellular States & Genetic Diversity in Glioblastoma, Mismatch Repair in Glioblastoma Resistance, Genetic Susceptibility in Brain Cancer, Pediatric Gliomas: Molecular Landscape & Emerging Targets, Molecularly Targeted Clinical Trials, Novel Radiation Sensitizers, Immunotherapy Checkpoint Inhibitors, Brain Tumor Vaccines, CAR T Cells, Oncolytic Virotherapy, Targeting Cancer Stem Cells, Therapeutic Delivery to CNS, Theranostics: Dual Modality PET Tracers, and Neuroimaging & Novel Response Assessments.
Citește tot Restrânge

Din seria The Clinics: Surgery

Preț: 80234 lei

Preț vechi: 84457 lei
-5% Nou

Puncte Express: 1204

Preț estimativ în valută:
15358 16687$ 12909£

Carte disponibilă

Livrare economică 31 martie-14 aprilie
Livrare express 15-21 martie pentru 3644 lei

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9780323813051
ISBN-10: 0323813054
Pagini: 240
Dimensiuni: 178 x 254 x 15 mm
Greutate: 0.51 kg
Editura: Elsevier
Seria The Clinics: Surgery


Descriere

This issue of Neurosurgery Clinics, guest edited by Dr. Linda M. Liau, is dedicated to Glioblastoma: Molecular and Clinical Trials. This issue is one of four selected each year by the series consulting editors, Drs. Russell R. Lonser and Daniel K. Resnick. Topics will include-but are not limited to-Pathology & Molecular Markers, Cellular States & Genetic Diversity in Glioblastoma, Mismatch Repair in Glioblastoma Resistance, Genetic Susceptibility in Brain Cancer, Pediatric Gliomas: Molecular Landscape & Emerging Targets, Molecularly Targeted Clinical Trials, Novel Radiation Sensitizers, Immunotherapy Checkpoint Inhibitors, Brain Tumor Vaccines, CAR T Cells, Oncolytic Virotherapy, Targeting Cancer Stem Cells, Therapeutic Delivery to CNS, Theranostics: Dual Modality PET Tracers, and Neuroimaging & Novel Response Assessments.